Depression Risk and Your Genetics

By the ExomeDNA Research Team | Last reviewed 2026-05-29

This page contains general information only. For personal health decisions, consult a qualified clinician.

Depression risk — measured here as genetic predisposition toward broad depression phenotypes — is a complex, polygenic trait shaped by dozens of identified genetic variants acting across brain chemistry, neural circuit structure, and cellular stress responses. Large-scale genome-wide association studies have identified multiple loci, with replication in cohorts exceeding 300,000 individuals. Below: how specific genes influence vulnerability, what the current research establishes, and what lifestyle factors the evidence most consistently supports.

What is Depression Risk?

Depression risk is a measure of genetic predisposition toward depressive symptoms and major depressive episodes, derived from polygenic scoring across many common variants. Genetic factors account for an estimated 30–40% of variance in depression risk, with environmental experiences accounting for the remainder. No single variant determines outcome; the score reflects cumulative signal across multiple biological pathways.

Research over the past decade has moved from single-gene candidate studies — which produced largely unreliable findings — toward large genome-wide association studies (GWAS) with hundreds of thousands of participants. This shift produced the first robust, replicated genetic associations for depression. The associations identified so far implicate pathways involving ion channel signaling, synaptic architecture, myelination, and oxidative stress defense — each offering a distinct biological window into why some people are more vulnerable to depressive episodes than others.

It is important to note that a higher genetic score here reflects an elevated population-level signal, not a certainty. Many people with high polygenic scores never develop clinical depression; many people with lower scores do. Environment, life history, social support, and access to care all shape whether genetic predisposition translates into lived experience.

The genetics behind Depression Risk

Five genes anchor the current biological picture for this trait: ASIC2, ACTR3B, ADGRG6, CCS, and ASTN1. Each operates through a distinct mechanism.

ASIC2 — acid-sensing in emotion circuits. ASIC2 encodes acid-sensing ion channel 2, a proton-gated cation channel that opens when extracellular pH drops in brain tissue. Neuroinflammation and intense neural activity both lower local brain pH, and ASIC2 in the amygdala, hippocampus, and dorsal raphe responds to these pH shifts by changing neuronal firing patterns. The dorsal raphe is the brain's primary serotonin-producing region; ASIC2 activity there may modulate serotonin release in response to metabolic and inflammatory stress. Animal studies using ASIC inhibitors show antidepressant-like effects, supporting the idea that ASIC2 variants affecting pH-triggered limbic circuit responses contribute to depression vulnerability. This mechanism — brain acidity as an emotional signal — is a relatively recent addition to depression biology and is not yet widely covered in consumer-genetics contexts.

ACTR3B — dendritic spine remodeling. ACTR3B encodes actin-related protein 3B, a component of the ARP2/3 complex responsible for branching the actin filaments that build dendritic spines. Dendritic spine density loss in the prefrontal cortex is one of the most consistently replicated structural findings in postmortem studies of clinical depression. ACTR3B variants that affect ARP2/3 function impair the structural synaptic plasticity that underlies both learning and recovery from stress — connecting a molecular scaffolding protein to one of depression's most visible anatomical signatures.

ADGRG6 — myelination and circuit integrity. ADGRG6 (also known as GPR126) is an adhesion G-protein coupled receptor required for peripheral and central myelination. Myelin is the insulating sheath around nerve fibers that governs transmission speed and synchrony across neural circuits. White matter tract integrity is measurably altered in people experiencing depression, and myelination defects affect how quickly and reliably signals move between brain regions involved in mood regulation. ADGRG6 variants that compromise myelination may subtly degrade the circuit-level coordination that stable mood depends on.

CCS — oxidative stress defense. CCS encodes the copper chaperone for superoxide dismutase. It delivers copper to SOD1 (Cu/Zn-superoxide dismutase), the enzyme responsible for neutralizing superoxide radicals in neurons. Neurons are particularly vulnerable to oxidative stress; CCS deficiency reduces active SOD1 and allows reactive oxygen species to accumulate. Neuroinflammation-related oxidative stress is increasingly recognized as a component of depression biology, and CCS variants that compromise this antioxidant pathway may raise cellular stress burden in neural tissue.

ASTN1 — cortical circuit architecture. ASTN1 encodes astrotactin 1, a neuronal migration guidance protein involved in establishing correct cortical layering during brain development. Subtle disruptions to cortical circuit architecture during development may shape how emotion-regulation circuits are organized, with downstream effects that persist into adult mood function.

Large-scale GWAS evidence: A 2018 genome-wide association study in UK Biobank analyzed both broad depression and International Classification of Diseases-defined major depressive disorder phenotypes, identifying multiple genome-wide significant loci and linking depression genetics to educational attainment and neuroticism pathways.^[1]

Sex-specific architecture: A 2023 sex-specific GWAS of depression phenotypes in UK Biobank identified distinct genetic signals in males versus females, underscoring that depression's polygenic architecture is not uniform across sexes and that population-level risk scores may capture different underlying biology depending on the individual.^[2]

What the research says

Research base: Robust. Depression genetics has been studied across multiple large cohorts involving hundreds of thousands of participants, with replicated associations across independent datasets and ancestrally diverse samples. The field moved decisively from candidate-gene approaches to well-powered GWAS after 2016, and the findings since have been consistent and replicable (Howard et al. 2018; Silveira et al. 2023).

The 2018 Howard et al. GWAS in UK Biobank was a landmark study, finding significant associations with broad depression phenotypes and demonstrating that depression GWAS signals overlap substantially with traits such as neuroticism and educational attainment — suggesting shared polygenic architecture across related psychological outcomes. This cross-trait overlap is informative: it suggests depression polygenic risk does not operate in a biologically isolated compartment but rather reflects broader emotional and cognitive circuitry (Howard et al. 2018).

The 2023 Silveira et al. sex-specific analysis added an important layer by showing that male and female depression phenotypes have partially distinct genetic architectures in UK Biobank data. This has practical implications for how population-level risk scores should be interpreted: a score derived from a mixed-sex cohort may not capture the full picture for either sex individually.

It is worth noting that, like most complex traits, the individual genetic variants identified so far each explain a very small fraction of overall variance. The polygenic score aggregates many small signals. This means the score performs better at the population level — distinguishing higher- from lower-risk groups in aggregate — than at the individual level. Individual outcome depends heavily on environmental factors.

For the full confidence-weighting and ancestry calibration framework underlying percentile scores in your ExomeDNA report, see our methodology page.

How Depression Risk affects you

A higher score on this trait reflects an elevated genetic signal toward depression vulnerability. The practical implications are not deterministic. Depression involves gene-environment interactions, and many people with higher polygenic scores lead lives with no significant depressive episodes, particularly when protective environmental and social factors are present.

What the genetics does reflect, at a mechanistic level, are differences in how the brain handles several categories of biological stress:

• pH shifts in limbic circuits — ASIC2 variants may alter how sensitively emotion-regulating brain regions respond to changes in local tissue acidity driven by inflammation or intense neural activity.
• Synaptic structural plasticity — ACTR3B variants may affect how readily the prefrontal cortex rebuilds dendritic connections after stressful or depressing experiences.
• White matter integrity — ADGRG6 variants may subtly affect how well neural circuits communicate across brain regions involved in mood regulation.
• Oxidative stress load — CCS variants may affect how efficiently neurons neutralize reactive oxygen species during periods of neuroinflammation.

None of these mechanisms translates into a simple statement about how a given person will experience their mood. They are biological tendencies, not predetermined outcomes. The score situates a person in a population distribution — it does not forecast the future.

A lower score does not confer protection. Depression is common, multifactorial, and caused by many factors a polygenic score does not capture, including life events, trauma, chronic stress, sleep disruption, substance use, and medical conditions.

Working with your Depression Risk result

The evidence on modifiable factors that interact with polygenic depression risk converges most strongly on the following areas. Each item reflects a category supported by research in general populations; individual effect sizes vary.

1. Regular aerobic exercise. Physical activity has one of the most consistent evidence bases for depression prevention and symptom reduction among lifestyle factors. Exercise influences several of the biological pathways this trait's genes operate in, including neuroinflammation, oxidative stress, and synaptic plasticity. Research consistently shows reduced symptom burden with regular moderate-intensity aerobic activity.

2. Anti-inflammatory dietary patterns. Omega-3 fatty acids (particularly EPA and DHA) and Mediterranean-style dietary patterns have been associated with reduced depression risk in epidemiological and some intervention data. This dietary profile maps onto the CCS/oxidative stress and neuroinflammation mechanisms relevant to this trait.

3. Sleep consistency. Sleep disruption is both a symptom of depression and a biological contributor to it. Irregular sleep amplifies inflammatory signaling and degrades prefrontal function — overlapping with the circuit-integrity mechanisms ADGRG6 and ACTR3B influence. Consistent sleep timing, adequate duration, and attention to sleep quality are among the most evidence-backed behavioral targets.

4. Social connection and relational support. Strong social ties are among the most robustly replicated protective factors in depression epidemiology. A higher polygenic score does not alter this finding — the benefit of social connection holds across the genetic risk distribution.

5. Professional evaluation if symptoms arise. A polygenic risk score is not a clinical screening tool, and this result should not substitute for professional evaluation if you are experiencing depressive symptoms. Effective treatments for depression exist and work well for most people. If you are concerned about your mood, consulting a clinician is the appropriate next step.

6. Omega-3 supplementation considerations. Evidence on omega-3 supplementation for depression is mixed in clinical trial data, but the mechanism — anti-inflammatory, neuroprotective — aligns with pathways relevant to this trait. Discuss with a clinician whether this makes sense for your situation.

Related traits and genes

Depression Risk shares biological overlap with several other traits in your ExomeDNA profile. Each has its own genetic story, but they reflect partly overlapping circuitry and mechanisms:

• Anxiety Tendency — polygenic architecture for anxiety and depression overlaps substantially; shared limbic circuit involvement and neuroticism-related loci connect the two.
• Stress Response (Cortisol) — the HPA axis stress response system interacts with depression vulnerability; chronic stress activation is a key environmental trigger.
• Neuroinflammation Tendency — oxidative stress and inflammatory signaling, relevant to the CCS pathway, connect depression to broader inflammatory biology.
• Sleep Quality — sleep and depression share bidirectional biological relationships; polygenic signals partially overlap.
• Cognitive Resilience — prefrontal circuit integrity, relevant to ACTR3B and ADGRG6, shapes both cognitive function and mood regulation.

Frequently asked questions

Is a higher Depression Risk score a clinical finding?

No. A polygenic risk score is not a clinical assessment and cannot determine whether any individual will experience depression. The score reflects where a person falls in a population distribution of genetic signals — it does not predict the future. Many people with higher scores never develop clinical depression, and depression is common among people across the entire score range. A clinician using validated symptom measures is the appropriate source for any depression evaluation.

What biological mechanisms does this score reflect?

This score aggregates genetic signals across pathways involved in acid-sensing in limbic circuits (ASIC2), dendritic spine remodeling in the prefrontal cortex (ACTR3B), myelination and neural circuit transmission (ADGRG6), oxidative stress defense in neurons (CCS), and cortical circuit architecture (ASTN1). These mechanisms represent distinct biological windows into depression vulnerability rather than a single cause. The novelty of the ASIC2 mechanism — brain pH shifts as emotional signals — illustrates how much is still being discovered about depression biology.

Can lifestyle changes reduce genetic depression risk?

The genetics cannot be changed, but the biological pathways they influence can be modulated by behavior. Regular aerobic exercise, anti-inflammatory dietary patterns, consistent sleep, and strong social connection have the most consistent evidence as protective factors in depression epidemiology. These factors work across the full range of genetic risk scores. A higher score is a signal to take these protective factors seriously — not a verdict on outcomes.

Is this trait relevant for both men and women?

Yes, but the genetic architecture of depression differs somewhat by sex. Research from UK Biobank shows that male and female depression phenotypes have partially distinct polygenic signals (Silveira et al. 2023). Population-level risk scores derived from mixed-sex cohorts capture overlapping but not identical biology. ExomeDNA's score reflects the best available population signal; future sex-stratified scoring may refine estimates as data matures.

Should I share this result with a mental health professional?

If you are currently working with a mental health clinician, sharing genetic risk information can be a useful addition to the conversation — your clinician can contextualize what the score means alongside your clinical history, current symptoms, and other risk factors. A polygenic score is one data point. It does not replace a clinical assessment and should not be used to make decisions about starting or stopping any treatment.

How does this score relate to family history of depression?

Family history is a proxy for genetic (and shared environmental) risk. A higher polygenic score and a family history of depression both point toward elevated genetic predisposition, and they often co-occur. A higher score with a significant family history suggests a genuinely elevated genetic signal. A lower score with a strong family history does not mean the family history is wrong — current GWAS panels capture only a portion of total genetic variance, and family history may reflect genetic factors not yet identified.

References

1. Howard DM, Adams MJ, Clarke TK, et al. (2018). Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nature Neuroscience, 22(3), 343–352. PMID: 29662059.

2. Silveira PP, Pokhvisneva I, Parent C, et al. (2023). A sex-specific genome-wide association study of depression phenotypes in UK Biobank. Nature Communications (2023). PMID: 36750733.

Data sources:

• GWAS Catalog (NHGRI-EBI, accessed 2026-05-29)
• Open Targets Platform (CC0 1.0, accessed 2026-05-29)
• ClinVar (NCBI, accessed 2026-05-29) — entries at ≥2-star review status
• ClinGen Gene-Disease Validity (CC0 1.0, accessed 2026-05-29)

Wellness Information. ExomeDNA provides educational interpretation of genetic variants for general wellness purposes only. This is not a clinical assessment, treatment recommendation, or clinical genetic test. Consult a healthcare provider before making health decisions. See our methodology and test limitations for details.

This page is published by ExomeDNA. We interpret raw genetic data into educational genetic insights using polygenic scoring with ancestry calibration. Read our methodology for the full statistical approach.

Last reviewed: 2026-05-29.

ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance.